We did a double-blind , phase 3 trial in patients with stage III cutaneous melanoma ( excluding lymph node metastasis 1 mm or in-transit metastasis ) with adequate resection of lymph nodes ( ie , the primary cutaneous melanoma must have been completely excised with adequate surgical margins ) who had not received previous systemic therapy for melanoma from 91 hospitals located in 19 countries .